Analysis of zoledronic acid prescribing and profile of patients treated

被引：0
|
作者：
Pardo-Pastor, J. [1 ]
Modamio, P. [1 ]
Pardo, C. [2 ]
Lastra, C. F. [1 ]
Mas, P. [2 ]
Marino, E. L. [1 ]
机构：
[1] Univ Barcelona, Dept Pharm & Pharmaceut Technol, Clin Pharm & Pharmacotherapy Unit, Barcelona, Spain
[2] Fundacio Hosp Asil de Granollers, Hosp Pharm, Barcelona, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2013年 / 35卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：995 / 995
页数：1
相关论文
共 50 条
  • [31] Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid
    Pectasides, D
    Nikolaou, M
    Farmakis, D
    Kanakis, I
    Gaglia, A
    Kountourakis, P
    Karamanos, NK
    Economopoulos, T
    Raptis, SA
    [J]. ANTICANCER RESEARCH, 2005, 25 (2B) : 1457 - 1463
  • [32] MODELING AND SIMULATION OF FRACTURE RISK IN JAPANESE OSTEOPOROSIS PATIENTS TREATED WITH ZOLEDRONIC ACID.
    Kasai, H.
    Mori, Y.
    Ose, A.
    Shiraki, M.
    Tanigawara, Y.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S100 - S101
  • [33] Osteonecrosis of the jaw in cancer patients with bone metastases treated with zoledronic acid: The focus is prevention
    Vormola, R.
    Ortega, C.
    Montemurro, F.
    Faggiuolo, R.
    Nanni, D.
    Goia, F.
    Aglietta, M.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI72 - XI72
  • [34] Impairment of renal function in the breast cancer patients with bone metastases treated with zoledronic acid
    Ito, Tokiko
    Ono, Mayu
    Oba, Takaaki
    Hanamura, Toru
    Kanai, Toshiharu
    Maeno, Kazuma
    Hiraguri, Manabu
    Shingu, Kiyoshi
    Kaneko, Gengo
    Ito, Ken-ichi
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [35] Overall Survival Among Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL)
    Berenson, J. R.
    Yellin, O.
    Crowley, J.
    Makary, A.
    Gravenor, D. S.
    Yang, H. H.
    Upadhyaya, G. H.
    Flinn, I. W.
    Staszewski, H.
    Tiffany, N. M.
    Sanani, S.
    Farber, C. M.
    Morganstein, N.
    Duvivier, H.
    Nassir, Y.
    Sefaradi, A.
    Shamouelian, A.
    Swift, R. A.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S12 - S13
  • [36] Determinants of response in patients with Paget's disease treated with zoledronic acid versus risedronate
    Hosking, DJ
    Miller, P
    Brown, J
    Fraser, W
    Lyles, K
    Reid, I
    Mesenbrink, P
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S670 - S671
  • [37] IMPAIRMENT OF RENAL FUNCTION IN THE BREAST CANCER PATIENTS WITH BONE METASTASES TREATED WITH ZOLEDRONIC ACID
    Ito, T.
    Shingu, K.
    Kaneko, G.
    Ito, K. -I.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [38] Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients.
    Myers, B
    Jones, SG
    McMillan, AK
    Dolan, G
    [J]. BLOOD, 2002, 100 (11) : 211A - 211A
  • [39] Factors that determine overall survival among patients with multiple myeloma treated with zoledronic acid
    Yellin, O.
    Crowley, J.
    Swift, R.
    Duvivier, H.
    Nassir, Y.
    Berenson, J.
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 : 29 - 30
  • [40] Two cases of brown tumour treated with zoledronic acid
    Pratama, E. P.
    Farida, A.
    [J]. HISTOPATHOLOGY, 2022, 81 : 181 - 181
12345